ArticleToxins2020
Assessment of Food By-Products' Potential for Simultaneous Binding of Aflatoxin B1 and Zearalenone.
Article in Toxins, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 15 citations in OpenAlex.
- Review
- Microbiome-mycotoxin interactions and probiotic strategies: implications for gut health and cancer.Frontiers in nutrition · 2026Review
- Article
- Article
- The Preferential Therapeutic Potential ofToxins · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
In this study, eight food by-products were investigated as biosorbent approaches in removing mycotoxin load towards potential dietary inclusion in animal feed. Among these food-derived by-products, grape seed (GSM) and seabuckthorn (SBM) meals showed the most promising binding capacity for Aflatoxin B1 (AFB1) and Zearalenone (ZEA), measured as percent of adsorbed mycotoxin. Furthermore, we explored the mycotoxin sequestering potential by screening the effect of time, concentration, temperature and pH. Comparative binding efficacy was addressed by carrying out adsorption experiments in vitro. The highest mycotoxin adsorption was attained using 30 mg of by-product for both GSM (85.9% AFB1 and 83.7% ZEA) and SBM (68% AFB1 and 84.5% ZEA). Optimal settings for the experimental factors were predicted employing the response surface design. GSM was estimated to adsorb AFB1 optimally at a concentration of 29 mg/mL, pH 5.95 and 33.6 °C, and ZEA using 28 mg/mL at pH 5.76 and 31.7 °C. Favorable adsorption of AFB1 was estimated at 37.5 mg of SBM (pH 8.1; 35.6 °C), and of ZEA at 30.2 mg of SBM (pH 5.6; 29.3 °C). Overall, GSM revealed a higher binding capacity compared with SBM. In addition, the two by-products showed different specificity for the binary-mycotoxin system, with SBM having higher affinity towards ZEA than AFB1 (K
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.